Search results
GSK Completes Demerger of Consumer Healthcare Business
Zacks via Yahoo Finance· 2 years agoPost demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer...
Is GSK Stock Worth Buying Right Now?
Motley Fool· 11 months agoGSK (NYSE: GSK), a global healthcare company, initiated the separation of its consumer healthcare business, Haleon, last year, as part of its ambitious...
GSK to sell 2.9% stake in former consumer healthcare business Haleon
Reuters via AOL· 9 months agoThe sale will bring down GSK's current 10.3% holding in the Sensodyne maker, which was spun out and...
GSK Trims Stake On Consumer Business Spin Off, Raises £804M
Benzinga via Yahoo Finance· 1 year agoGSK Plc (NYSE: GSK) sold 240 million shares of its spun-out consumer healthcare group Haleon Plc...
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
Zacks via Yahoo Finance· 2 years agoGSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises...
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
Zacks via Yahoo Finance· 2 years agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
GSK to divest remaining 4.2% stake in Haleon
Pharmaceutical Technology via Yahoo Finance· 1 month agoGSK has announced its intention to divest approximately 385 million ordinary shares in consumer healthcare company Haleon. This equates to approximately...
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
Zacks via Yahoo Finance· 7 months agoStrong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and...
This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"
Benzinga via Yahoo Finance· 2 years agoCiti group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc...
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
Zacks via Yahoo Finance· 3 months agoStrong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and...